10.1007/s40204-015-0037-z

Assessment of lactoferrin-conjugated solid lipid nanoparticles for efficient targeting to the lung

HTML PDF
  • Satish Shilpi*1,
  • Vishnoo Dayal Vimal2,
  • Vandana Soni2,
  1. Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University, Sagar, Madhya Pradesh, 470 003, IN Ravishankar College of Pharmacy, Bhopal, Madhya Pradesh, 462 010, IN
  2. Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University, Sagar, Madhya Pradesh, 470 003, IN
Cover Image

Published in Issue 2015-03-27

How to Cite

Shilpi, S., Vimal, V. D., & Soni, V. (2015). Assessment of lactoferrin-conjugated solid lipid nanoparticles for efficient targeting to the lung. Progress in Biomaterials, 4(1 (March 2015). https://doi.org/10.1007/s40204-015-0037-z
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Abstract The aim of the present study was to develop a target oriented drug delivery system for the lungs. Lactoferrin (Lf)-coupled solid lipid nanoparticles (SLNs) bearing rifampicin was prepared by a solvent injection method. The prepared nanoparticles were characterized for shape, particle size, polydispersity and percentage drug entrapment. An optimized formulation was then studied for its in vivo performance in animals and to determine its targeting efficiency. It was observed that, upon coupling with Lf, the size of SLNs increased while the percent entrapment efficiency decreases. In in vitro release, determined by a dialysis technique, analysis showed that uncoupled SLNs exhibited higher drug release as compared to coupled SLNs. An in vivo biodistribution study shows 47.7 ±0.4 drug uptakes by the lungs, which was 3.05 times higher in comparison to uncoupled SLNs. These biodistribution studies are further supported by the fluorescence study that revealed enhanced uptake of Lf-coupled SLNs in the lung. From the presented results, it can be concluded that Lf-coupled SLNs enhanced drug uptake in the lung. Moreover, lactoferrin is an efficient molecule that can be used for targeting active agents directly to the lung.

Keywords

  • Biodistribution,
  • Lung targeting,
  • SLNs,
  • Drug delivery,
  • Lactoferrin
HTML PDF

References

  1. Allen (2002) Ligand targeted therapeutic in anticancer therapy https://doi.org/10.1038/nrc903
  2. Alpiaz et al. (2008) Solid lipid microparticles for the stability enhancement of the polar drug N-6-cyclopentyladenosine 355(1–2) (pp. 81-86) https://doi.org/10.1016/j.ijpharm.2007.11.044
  3. Anisimova et al. (2000) Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages (pp. 165-171) https://doi.org/10.1023/A:1010061013365
  4. Baek and Cho (2013) 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells 65(1) (pp. 72-78) https://doi.org/10.1111/j.2042-7158.2012.01578.x
  5. Calleja et al. (2004) High-performance liquid-chromatographic determination of Rifampicin in plasma and tissues (pp. 289-294) https://doi.org/10.1016/j.chroma.2003.12.041
  6. Carneiro et al. (2012) Formation of ion pairing as an alternative to improve encapsulation and anticancer activity of all-trans retinoic acid loaded in solid lipid nanoparticles (pp. 6011-6020)
  7. Deol and Khuller (1997) Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice (pp. 161-172) https://doi.org/10.1016/S0304-4165(96)00088-8
  8. Elfinger et al. (2007) Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells (pp. 3448-3455) https://doi.org/10.1016/j.biomaterials.2007.04.011
  9. Fry (1978) Rapid separation of low molecular weight solutes from liposomes without dilution (pp. 803-807) https://doi.org/10.1016/0003-2697(78)90172-0
  10. Gupta et al. (2007) Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain (pp. 1-6) https://doi.org/10.1211/jpp.59.7.0004
  11. Ito and Makino (2004) Preparation and properties of monodispersed Rifampicin loaded poly(lactide-co-glycolide) microspheres (pp. 17-21) https://doi.org/10.1016/j.colsurfb.2004.08.016
  12. Jaspart et al. (2005) Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications 2(1) (pp. 75-87) https://doi.org/10.1517/17425247.2.1.75
  13. Kar (2005) New Age International Publishers
  14. Loira-Pastoriza et al. (2014) Delivery strategies for sustained drug release in the lungs (pp. 81-91) https://doi.org/10.1016/j.addr.2014.05.017
  15. Makino et al. (2004) Efficient intracellular delivery of Rifampicin to alveolar macrophages using Rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of Rifampicin (pp. 35-42) https://doi.org/10.1016/j.colsurfb.2004.03.018
  16. Muller and Keck (2010) Pharmaceutical nanoparticles-from their innovative origin to their future (pp. 1-3) https://doi.org/10.1016/j.ijpharm.2010.02.005
  17. Nassimi et al. (2010) A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung 75(2) (pp. 107-116) https://doi.org/10.1016/j.ejpb.2010.02.014
  18. O’Hara and Hickey (2000) Respirable PLGA microspheres containing Rifampicin for the treatment of tuberculosis: manufacture and characterization (pp. 955-961) https://doi.org/10.1023/A:1007527204887
  19. Pandey and Khuller (2005) Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis (pp. 227-234) https://doi.org/10.1016/j.tube.2004.11.003
  20. Pandey et al. (2005) Oral solid lipid nanoparticle-based anti-tubercular chemotherapy 85(5–6) (pp. 415-420) https://doi.org/10.1016/j.tube.2005.08.009
  21. Sahu PK, Mishra DK, Jain N, Rajoriya V, Jain AK (2014) Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel. Drug Dev Ind Pharm (epub ahead of print)
  22. Schubert and Goymann (2003) Solvent injection as a new approach for manufacturing lipid nanoparticles evaluation of the method and process parameters (pp. 125-131) https://doi.org/10.1016/S0939-6411(02)00130-3
  23. Sharma et al. (2004) Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis 54(4) (pp. 761-766) https://doi.org/10.1093/jac/dkh411
  24. Shuhendler et al. (2012) A novel solid lipid nanoparticle formulation for active targeting to tumor α (v) β (3) integrin receptors reveals cyclic RGD as a double-edged sword 1(5) (pp. 600-608) https://doi.org/10.1002/adhm.201200006
  25. Tomoda and Makino (2007) Effects of lung surfactants on Rifampicin release rate from monodisperse Rifampicin-loaded PLGA microspheres (pp. 115-124) https://doi.org/10.1016/j.colsurfb.2006.11.030
  26. Tomoda et al. (2005) Effects of pulmonary surfactant system on Rifampicin release from Rifampicin-loaded PLGA microspheres (pp. 1-6) https://doi.org/10.1016/j.colsurfb.2005.06.014
  27. Tsuda et al. (2002) Cancer prevention by bovine lactoferrin and underlying mechanisms-a review of experimental and clinical studies (pp. 131-136) https://doi.org/10.1139/o01-239
  28. Wang et al. (2012) The improvement of the anticancer effect of a novel compound benzoic acid, 2-hydroxy-, 2-D-ribofuranosylhydrazide (BHR) loaded in solid lipid nanoparticles 13(4) (pp. 1348-1354) https://doi.org/10.1208/s12249-012-9862-8
  29. Wissing and Muller (2002) Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration (pp. 225-233) https://doi.org/10.1016/S0168-3659(02)00056-1
  30. Yang et al. (2012) Biodegradable solid lipid nanoparticle flocculates for pulmonary delivery of insulin 8(5) (pp. 834-842) https://doi.org/10.1166/jbn.2012.1429
  31. Zhou et al. (2005) Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages (pp. 288-299) https://doi.org/10.1016/j.jconrel.2005.06.009
  32. Zhuang et al. (2012) Solidlipidnanoparticlesof anticancer drugs against MCF-7 cell line and a murine breast cancer model 67(11) (pp. 925-929)